FAQ: How does the guselkumab data align with the STRIDE II guidelines?
GHAPPcast25 Feb 2025

FAQ: How does the guselkumab data align with the STRIDE II guidelines?

Thank you to Johnson & Johnson for your support of this FAQ Video Module.

In this video, Erin Darguzas, NP, from the Inflammatory Bowel Disease Center at Northwestern Medicine, discusses how Guselkumab data aligns with STRIDE II guidelines for monitoring IBD (Inflammatory Bowel Disease) patients over time. Developed by International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) members, STRIDE II provides a treat-to-target framework that outlines short-term, intermediate, and long-term goals for achieving disease control.

Erin explains how Guselkumab's clinical trials align with these treatment targets. In induction studies, patients were evaluated at Baseline and Week 12, with clinical remission as the primary outcome—matching STRIDE II's short-term targets. The results showed symptom improvement and mucosal healing by Week 12, supporting early treatment efficacy.

In maintenance trials, clinical responders from the induction phase were randomized into maintenance arms, with Week 44 clinical remission as the primary endpoint. Additional key outcomes included corticosteroid-free remission, sustained clinical response, endoscopic improvement, and mucosal healing—meeting intermediate and long-term STRIDE II targets.

By demonstrating both short- and long-term efficacy, Guselkumab shows potential for long-term IBD management in alignment with STRIDE II treatment goals. For more expert insights on IBD treatment strategies, visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(155)

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Jun 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Mai 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Mai 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Mai 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Mai 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Mai 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Populært innen Helse

fastlegen
rss-gukild-johaug
lydartikler-fra-aftenposten
psykodrama
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
foreldreradet
rss-skravla-gar
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
rss-garne-damer
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
rss-lopedrommen
hjernesterk
g-punktet
treningsprat
rss-kull
sinnsyn
hverdagspsyken